From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Advanced. Automated. Affordable.
Learn more
FDA-cleared AXINON®System is our core technology platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.
Locations: The Woodlands, Texas;
Regensburg, Germany
Employees of medical and
scientific disciplines
Founded as a spin-off of
Regensburg University, Regensburg, Germany
Analyses worldwide
Numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet health care needs not addressed by single biomarker-based medicine.
Our diagnostic tests are based on the interpretation of multiple biomarkers that precisely pinpoint relevant data related to organ function. With these next-generation metabolite constellations, we develop non-invasive diagnostic tests that provide more precise information than the current standard tests.
- Chairman, Supervisory Board
- Managing Partner, SHS Capital
- More than 20 years’ experience in private equity
- Former CEO at numares
- Previously with Roche and McKinsey
- Previously Managing Director of Mayfair SE
- Previously board member at Tchibo
- Supervisory board member at Puma
- Previously Senior Director at Mayo Clinic
- Steering committee member of numares-Mayo collaboration
- Previously with Oncospire Genetics and Roche
- Founder and CEO of DiaMedCare
- Previously with Novartis Ciba Geigy
- Previously with McKinsey
- Founder and CEO of kineo finance AG (formerly DiaMedCare AG)
- Scientific Advisory Board of Everly Health
- Strategic and scientific advisor
- Previously with Roche and Illumina